Your browser doesn't support javascript.
loading
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
Boockvar, John A; Tsiouris, Apostolos J; Hofstetter, Christoph P; Kovanlikaya, Ilhami; Fralin, Sherese; Kesavabhotla, Kartik; Seedial, Stephen M; Pannullo, Susan C; Schwartz, Theodore H; Stieg, Philip; Zimmerman, Robert D; Knopman, Jared; Scheff, Ronald J; Christos, Paul; Vallabhajosula, Shankar; Riina, Howard A.
Affiliation
  • Boockvar JA; Departments of Neurosurgery, Weill Medical College of Cornell University, 510 East 70th Street, New York, New York 10021, USA. jab2029@med.cornell.edu
J Neurosurg ; 114(3): 624-32, 2011 Mar.
Article in En | MEDLINE | ID: mdl-20964595

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Blood-Brain Barrier / Angiogenesis Inhibitors / Glioma / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurosurg Year: 2011 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Blood-Brain Barrier / Angiogenesis Inhibitors / Glioma / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurosurg Year: 2011 Type: Article Affiliation country: United States